Financing channel feed – Endpoints News

Financing channel feed

Atlas, F-Prime provide launch money for Akrevia — a little biotech with big plans to design better drugs

7 years ago

Nasdaq triple IPO play brings in $345M as the big biotech party rocks on

7 years ago

AstraZeneca-backed Entasis Therapeutics joins the IPO class of 2018 with a weak debut price

7 years ago

Lyra pockets $29.5M to push ear, nose, throat applications of implant tech from Langer, Whitesides

7 years ago

Guest column: The 3 big waves reshaping investment strategies in early-stage biotech

7 years ago

Praveen Tipirneni's team at Morphic reels in an $80M round as they turn into the last stretch to the clinic — and a deal

7 years ago

PhaseBio details dollars in AstraZeneca deal as it rolls out a plan for $86M-plus IPO

7 years ago

Fresh from the Novartis/Trump scandal, ex-CEO Joe Jimenez jumps on the board of uBiome — a biotech launching an R&D group

7 years ago

Nasdaq parade marches on as ex-Genmab crew at Y-mAbs reaps $96M

7 years ago

Ron DePinho raises seed cash for MD Anderson colleague's work on a 'Holy Grail molecule' in cancer, inflammation

7 years ago

Drumbeat of bad news continues at OncoMed as Celgene dumps option on one of its last pipeline efforts

7 years ago

With new $10.6B fund, Hillhouse Capital sets the stage for splashy Asia-focused biotech deals

7 years ago

Two Genentech vets reunite at Immune-Onc to help steer its $33M drive to the clinic

7 years ago

Silverback starts to slowly edge out of stealth mode — but there’s still plenty being kept under wraps

7 years ago

Clarus spearheads a big, $150M raise so Galera can flip the PhIII card on its new drug to treat radiation effects

7 years ago

WuXi AppTec files for public listing in Hong Kong four months after explosive Shanghai IPO

7 years ago

Launch a new company, steer a $150M IPO and ink a big data collaboration — they call it Monday at Vivek Ramaswamy’s Roivant

7 years ago

After a 6-month romp, Arie Belldegrun and David Chang fly a $100M-plus IPO for off-the-shelf CAR-T player Allogene

7 years ago

Upsized and top-of-the-range: Fall round of biotech IPOs starts with a solid hit for Principia

7 years ago

Scouting early-stage oncology plays, biopharma vets Detlev Biniszkiewicz, Scott Chappel make VC debut at MPM

7 years ago

Vivo Capital bags $635M for its new biotech public company fund

7 years ago

Mike Narachi gets a $19M shot at a new approach to gene therapy — and he has another big market in mind

7 years ago

Atreca banks a $125M mega-round as it builds a pipeline of antibodies for cancer and ponders IPO timing

7 years ago

Focusing on the tumor microenvironment, OncoResponse garners $40 million for the next stage of the R&D journey

7 years ago

First page Previous page 121 122 123124125 126 127 Next page Last page